for the use only of a
registered medical practitioner or a hospital or a laboratory.
EXPERIENCE WITH R. COMPOUND
IN
RHEUMATOID ARTHRITIS.*
By
Dr. J.S. Makhani, M.Sc. (Mc Gill) FRCS (C) FACS
Professor & Head, Department of Orthopaedic Surgery Goa Medical College,
Panaji Formerly JIPMER, Pondicherry
Paper presented at
the XXIX Annual Conference of the Association of Physicians of India, Patna,
January, 1974 and XXXIII Annual Conference of Association of Surgeons of India.
Trivandrum
January - February, 1974.
-The Clinician Vol. 40, No. 8, PP 312-17, Aug. 1976
INTRODUCTION
Therapeutic measures for
rheumatoid arthritis include drugs (aspirin, analgesics, gold, antimalarials,
anti-inflammatory agents and corticosteroids), physical therapy, splintage and
various orthopaedic procedures, and each of these has a specific role in
limiting the disease process. Response to drugs vary considerably not only in
different patients but even in the same individual on different occasions, and
thus this disease orfers a great challenge to the treating physician. Search
for a safe and effective drug is continuing because almost all drugs have some
side-effects and complications following prolonged use. Experience with R. Compound
is reported in this paper.
WHAT IS R. COMPOUND
R. Compound is an
ayurvedic drug produced by Alarsin, Bombay and supplied as dark brown tablets
of dull lustre. It contains Mahayograj Guggul, Maharasanadi quath and gold.
Mahayograj Guggul is prepared from 30 herbomineral drugs and has
"Guggul" as its main ingredient which is known to possess
anti-arthritic properties.3 Maharasandi quath is similarly prepared from 25
herbal drugs with "Rasna" as its main ingredient which is known to
possess anti-inflammatory properties.3 Gold is an important constituent of R.
Compound; it is present in the form of "ashes" or "bhasma"
and is also known to be anti-rheumatic.4 R. Compound contains 200 mg of
Mahayograj Guggul with gold and 67 mg of Maharasanadi quath.
METHOD AND MATERIAL
Diagnosis was based on the
criteria laid down by American Rheumatic Association and as suggested it was
possible to group 135
cases in this series into
classical (61 cases), definite (48 cases), probable (17 cases) and possible (9
cases).
INVESTIGATIONS:
Haemoglobin, R. B. C. total W. B. C., and differential counts, ESR, bleeding
and clotting time, serum cholesterol, uric acid, blood sugar, Rose-Waaler test,
urine and stool were routinely examined in all cases Radiological examination
of the affected joints was considered as essential and important investigation.
Features like synovial swelling, osteoporosis and osteoarticular damage were
noted to assess the status of the disease process. Whenever possible synovial
fluid was aspirated and biochemcal test including mucin test were carried out.
Special investigations included arthrography and synovial biopsies. These
investigations were periodically repeated during the course of the disease to
assess the progress.
MATERIAL :
135 cases of rheumatoid arthritis were included in this study: 82 were female
and 53 were male. Table I shows the age distribution: majority belonged to the
second to fourth decade. Monoarticular arthritis was found in 49 cases whereas
polyarticular arthritis was present in 86 cases. Arthrography was performed in
27 cases but was repeated only in 5 cases at varying intervals of therapy.
Similarly synovial biopsies were carried out in 63 cases and repeated in 5
cases in the form of synovectomy. Clinically two groups were formed. (a)
Arthritis without deformities (94 cases) in which joint pain, stiffness,
swelling and even constitutional symptoms were the presenting symptoms. Joint
swelling was caused by effusion and synovial thickness. Movements were
restricted due to muscle spasm, effusion, thickened synovium and osteoarticular
damage. Monoarticular lesions presented diagnostic problems and a synovial
biopsy was essential to establish the diagnosis (b) Arthritis with deformities
(18 cases), occurring in chronic and neglected cases in which almost all joints
were affected; varying in severity from flexion contracture to fibrous
ankylosis.
METHOD OF STUDY:
While various investigations, were completed no specific drug therapy was
given, and those already under therapy were weaned off before starting therapy
with R. Compound. In the second (occasionally third) week, R. Compound was
started in the recommended dose of 2 tablets thrice a day after meals and was
continued for variable period of 8 weeks to 2 years or more.
In another group placebo was given in similar doses for 2 weeks and if
unsatisfactory response was obtained, R. Compound therapy was started and
continued. For acute symptoms, supportive therapy and supplementary agents
were used whenever indicated. Surgery in the form of synovectomy, arthoplasty
or arthrodesis was considered when the synovial swelling did not subside, pain
persisted and deformities interfered with functional recovery.
ASSESSMENT:
Criteria as used in the diagnosis of rheumatoid arthritis were also used to
assess the therapeutic response; stiffness, pain, joint swelling, range of
movement, extent of deformity and functional disabilities were evaluated
periodically while stiffness and pain were purely subjective symptoms, swelling
of the joint especially of hands, knee etc., were measured using gold-smith's
rings and circumferential measurements. For each of these symptoms therapeutic
response was recorded as completely or partially relieved or no change to the
drug therapy. Range of movement of the various joints was recorded by the
physiotherapist before and during the therapy. Settling of temperature, ESR and
WBC counts to within normal values was also considered as criteria of
improvement and satisfactory response to therapy. Patients were advised to report
for check-up atleast once in 2 months. 5 patients on R. Compound and 8 from the
placebo group did not return for follow-up and thus 112 patients were followed
for sufficient period to assess the results of therapy.
RESULTS
Moderate degree of anemia
was often found in chronic polyarticular rheumatoid arthritis. Mild degree of
leucocytosis with shift to the left and lymphositosis was also found in similar
cases. Erythrocyte sedimentation rate was usually elevated and had a direct
relation to the activity of disease; it was over 100/mm in the first hour in 17
cases. Rose-Waaler test found of value in almost one-fourth of the cases.
Radiological examination of the various joints (Table II) showed findings which
ranged from normal appearance to definite osteo-articular damage (Table III).
Synovial fluid was examined in 26 cases and a poor mucin test was detected in
about half of them.
Arthrography of major
joints revealed synovial thickening, filling defects, associated meniscus and
osteo-articular damage, and an attempt was made to corelate the changes in
synovial thickening as seen before and after therapy. There is some evidence to
believe that regression in the synovial mass does occur with arrest of the
disease activity and this aspect of the study is further continued. In
resistant cases or those requiring surgery, histological changes in the
synovium were compared with those found in earlier biopsy but no definite
corelation could be established because repeat biopsies could not be performed
in cases which showed improvement.
Temperature usually
subsided within 7 to 10 days though in few patients it took 15 to 20 days,
whereas in one patient it took almost one month of treatment. On few occasions
the temperature re-appeared on stoppage of R. Compound and thus the drug had to
be continued for prolonged periods. ESR usually returned to normal values
within 15 to 20 days though it required about 45 days in a severely advanced
and active case. WBC count similarly, returned to normal values within 21
days. Majority of our patients remarked about the subjective feeling of
well-being and improvement in general health after prolonged therapy with R.
Compound.
Therapeutic response to R.
Compound in rheumatoid arthritis without deformities was assessed in 94 cases:
stiffness- 34 cases (36%) responded remarkably with complete recovery and 51
cases (54%) obtained only partial recovery while in 9 cases (10%) there was no
change at all. pain - 23 cases (24%) were completely or almost completely
relieved of pain, while 44 cases (47%) obtained only partial relief and in 27
cases (29%) pain was not relieved at all. Swelling- 15 cases (16%) showed complete
or almost complete remission of the joint swelling, 30 cases (32%) showed only
partial reduction of swelling, while in 49 cases (52%) no change occurred.
Considering complete and partial recovery together, satisfactory response for
stiffness was obtained in 90%, pain in 71 % and swelling in 48% cases; and
collectively for various symptoms complete recovery was obtained in 25.3%, partial
recovery in 44.4% and no change in 30%.
Therapeutic response in
rheumatoid arthritis with deformities was assessed in 18 cases: Stiffness-
only partial recovery was obtained in 6 cases (33%); the remaining did not show
any improvement.
Pain - only partial relief
was obtained in 5 cases (21%).
Swelling - only partial
reduction occured in 11 cases (61 %).
Deformity - only partial
reduction in the severity of deformity occured in 4 cases (22%). In this group
over-all improvement was obtained in only 34% of cases.
Of particular importance was the group of 10 patients of Polyarticular
rheumatoid arthritis treated earlier with steroids which required withdrawal of
the drug. There were 7 female and 3 male patients in this group; youngest was
14 years of age while the oldest was 50 years. Steroids had been given to these
patients for varying periods of 5 months to 10 years. 4 of these were bed
ridden and completely dependent for activities of daily living. In order to
wean them, steroid dose was gradually reduced. Splintage, physical therapy and
whenever necessary salicylates or other anti-rheumatic drugs were used to
control the acute symptoms. It required 3 to 6 weeks to completely wean these
patients. R. Compound was started in the later stages of weaning, and was
continued un-interruptedly while other supplementary drugs, if used, were
withdrawn. All the 10 patients were successfully weaned off steroids and have
been maintained on R. Compound since then. It was encouraging to note the
control of pain, vulnerability to physical therapy, control of constitutional
symptoms, improvement in general health, response to supportive measures and
overall change of outlook when the patients started to walk within 2 to 3
months period. Surgical treatment, whenever indicated, was well tolerated and
none of these patients required any further therapy with steroids.
TABLE 1
AGE DISTRIBUTION |
|
1 to 10 years |
6 cases |
11 to 20 years |
37 cases |
|
49 cases |
|
28 cases |
|
13 cases |
|
2 cases |
Total |
135 cases |
Table II
INCIDENCE OF JOINT INVOLVEMENT
|
|
Hip |
31 |
Knee |
92 |
Ankle & foot |
55 |
Shoulder |
21 |
Elbow |
47 |
Wrist & Hand |
56 |
Spine |
29 |
Table III
RADIOLOGICAL OBSERVATIONS
|
|
Normal Appearance |
17cases |
Soft Tissue Swelling |
24 cases |
Osteoporosis |
10 cases |
Swelling & Osteoporosis |
43 cases |
Osteo-articular changes |
41 cases |
DISCUSSION
Gum Guggul has since long
been used in ayurvedic System of medicine and preparations like Yograj Guggul
and Mahayograj Guggul are in common use for muscular rheumatism. They are said
to be more effective when administered along with "Rasna". Their
anti-arthritic and anti-inflammatory activity has been shown to reside in the
oleo-resin portion of the crude drug, and the active principle contained in it
appears to be highly potent.3 In an experimental study' using formalin induced
arthritis and croton oil granuloma pouch models, Karandikar et al showed that
Mahayograj Guggul, Maharasana and Sammirpannag Ras possess anti-inflammatory
effect; they also studied the adrenocortical activity and concluded that their
effect does not mediate through the pitutory adrenal axis but through some
other unknown mechanism.
R. Compound containing the
essential Mahayograj Guggul, Maharasandi quath and gold possesses
anti-rheumatic and anti-inflammato7 actions. 3, 5, 6, Various
clinical trials 7,8,9, 10, 11, 12,13,14, ". have shown the
usefulness of R. Compound in chronic arthritis especially rheumatoid arthritis.
Sardesai and Deshpande (1968) in a study of 32 cases of rheumatoid arthritis
reported satisfactory results for pain in 85% and joint movement in 80% whereas
Gupta et al (1968) concluded that cases having little deformity and pain
responded more favourably to R. Compound while it had no effect on
deformities, though swelling, pain and movement increased in 3 out of 8 cases.
Sancheti (1968), on the other hand, in a study of 14 Cases reported
improvement in inflammation, pain and movement even in advanced cases of
rheumatoid arthritis. In the present study cases of rheumatoid arthritis
without deformities showed satisfactory response for stiffness in 90%, pain in
71 %, and swelling in 48% cases; complete recovery from various symptoms occured
in 25.3% partial recovery in 44.4% while no change occured in 30.3%. On the
other hand, cases with deformities showed only partial recovery in 34% cases.
Opinion is already hardening against long term therapy with corticosteroids2
and in this study 1 patients treated with steroids were successfully weaned off
and put on R. Compound with satisfactory results.
In acute cases
supplementary drugs and splintage may be indicated to overcome the crisis.
Constitutional symptoms respond satisfactorily; subjective symptoms of
stiffness and pain are relieved in majority of the patients while swelling
responds rather slowly and hence the need for prolonged therapy.
Experience with 135 cases
of rheumatoid arthritis with the use of R. Compound is described in this
paper. R. Compound is a safe and useful drug and is highly recommended in
chronic cases of rheumatoid arthritis unassociated with deformities. It may,
however, be also used in patients with deformities, in conjunction with other
orthopaedic procedures. It is of particular significance in steroid treated
patients who need to be weaned off.
REFERENCES
1. Thompson, M. :
Rheumatoid Arthritis. Reports on Rheumatic Diseases. Published by the
Arthritis and Rheumatism Council, No. 44. June, 1971.
2. Choice of Analgesic for
Rheumatic Disorders. Reports on Rheumatic Diseases. Published by The Arthritis
and Rheumatism Council, No. 33. June, 1968.
3. Gujral, M. L; Sacreen,
K; Tangri, K. K; Amma, M. K. P; Roy, A. K. : Anti-arthritic and
Anti-inflammatory Activity of Gum Guggul (Balasamodendron Mukul Hook). Ind. J.
Phys. & Pharm. 4:267,1960.
4. Kaikini, V. M : Use of
Gold preparations in Rheumatoid Arthritis. The Antiseptic, 5:1, 1953.
5. Karandikar, G. K;
Gulati, O. D; Gokhale, S. D. : Anti-inflammatory Activity of some Ayurvedic
Remedies and their influence on the Hypophysea - Adrenocortical Axis in white
Rates. Ind. J. Med. Res. 43:482, 1960.
Experience and
observations in this study suggest that R. Compound is a safe, non-toxic,
anti-rheumatic drug with a simple dose regime; it may be increased to 12
tablets a day in resistant case and because of a wide margin of safety can be
continued for prolonged periods.
6. Prasad, D. N;
Satyawati, G. V; Dasgupta, B. V; Das, J. K. : Experimental Investigations on
R. Compound, SEAPALAR,1968.
7. Gupta, A. K; Rallan, R.
C; Ahuja, S. C.: Value of R. Compound in rheumatoid Arthritis, SEAPALAR, 1968.
8. Sardesai, H. V;
Deshpande, S. S.: Use of R. Compound in Rheumatoid Arthritis, SEAPALAR, 1968.
12. Ramachandran, K,: R.
Compound in Rheumatoid Arthritis. Mediscope, 15:2538,1972.
9. Subramaniam, R.: R.
Compound in Rheumatoid Arthritis. SEAPALAR, 1968.
13. Sancheti, K. N.: R.
Compound in Chronic Arthritis. SEAPALAR, 1968.
10. Patnaik, B. C. :
Clinical Trial with R. Compound in Rheumatoid and other Arthritis Disorders.
Current Medical practice 15:626-627,1971.
11. Ethirajulu, G.; Reddy,
J. V.: R. Compound in Rheumatoid Arthritis and other chronic Arthritides. Paper
presented at 4th A. P Chapter of Ass. Orth. Surg. Hyderabad, 1972.
14. Shanmugasundaram T. K;
DeSa, H : A double blind controlled Trial of R. Compound in 115 cases of
Rheumatoid Arthritis & Osteo-arthritis. Paper presented at V. Conference of
Tamil Nadu Orthopaedic Association, Madras, 1973.
for information on ALARSIN
products please write to : ALARSIN. Alarsin House, A/32, Road No. 3, M.LD.C.,
Andheri (E), Bombay-400 093.